COST-EFFECTIVENESS OF EVERY TWO MONTH CABOTEGRAVIR LONG-ACTING (CAB-LA) FOR PRE-EXPOSURE PROPHYLAXIS (PREP) COMPARED WITH DAILY ORAL TENOFOVIR DISOPROXIL FUMARATE (TDF)/ EMTRICITABINE (FTC) AS PREP TO PREVENT HIV-1 IN THE UK

被引：0
|
作者：
O'Brien, P. [1 ]
Campbell, K. [2 ]
Anderson, S. J. [3 ]
Cornic, L. [3 ]
Davis, A. [4 ]
Schroeder, M. [5 ]
机构：
[1] ViiV Healthcare, Limerick, LK, Ireland
[2] RTI Hlth Solut, Wolverhamptom, England
[3] GlaxoSmithKline, Brentford, England
[4] RTI Hlth Solut, Res Triangle Pk, NC USA
[5] ViiV Healthcare, Brentford, Hounslow, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE281
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 14 条
  • [1] COST-EFFECTIVENESS OF EVERY TWO MONTH CABOTEGRAVIR LONG-ACTING (CAB-LA) COMPARED WITH DAILYORALEMTRICITABINE(FTC)/TENOFOVIRDISOPROXIL FUMARATE (TDF) FOR PRE-EXPOSURE PROPHYLAXIS (PREP) TO PREVENT HIV-1 INFECTION IN THE UNITED STATES
    Davis, A. E.
    Brogan, A.
    Mellott, C. E.
    Fraysse, J.
    Oglesby, A.
    VALUE IN HEALTH, 2022, 25 (07) : S301 - S301
  • [2] COST-EFFECTIVENESS OF CABOTEGRAVIR LONG-ACTING FOR PRE-EXPOSURE PROPHYLAXIS VERSUS CURRENT USE OF DAILY ORAL TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE OR NO PREP TO PREVENT HIV-1 IN INDIVIDUALS AT HIGH RISK IN
    Neches, V
    Campbell, K.
    Coll, P.
    Guillen, Moreno S.
    Martinez-Sesmero, J. M.
    Segui, Lopez F.
    O'Brien, P.
    Davis, A.
    Anderson, S. J.
    Schroeder, M.
    Vallejo-Aparicio, L. A.
    VALUE IN HEALTH, 2024, 27 (12) : S121 - S121
  • [3] INDIRECT TREATMENT COMPARISON (ITC) OF CABOTEGRAVIR LONG ACTING (CAB-LA) FOR PRE-EXPOSURE PROPHYLAXIS (PREP) VERSUS NO PREP FOR HIV PREVENTION
    Hawkins, N.
    O'Brien, P.
    Thompson, J. C.
    Anderson, S. J.
    Manalastas, E.
    Dupont, Benjamin L.
    Schroeder, M.
    VALUE IN HEALTH, 2024, 27 (06) : S46 - S46
  • [4] Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis
    Chen, Xiu
    Li, Jun
    Kou, Liqiu
    Xie, Xiaolu
    Wei, Deqing
    Li, Yaling
    REVIEWS IN MEDICAL VIROLOGY, 2023, 33 (04)
  • [5] Transgender Women’s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)
    Christine Tagliaferri Rael
    Javier Lopez-Ríos
    Stacey A. McKenna
    Doyel Das
    Curtis Dolezal
    Elena Abascal
    Alex Carballo-Diéguez
    Rebecca Schnall
    Thomas J. Hope
    José Bauermeister
    Walter Bockting
    AIDS and Behavior, 2021, 25 : 4180 - 4192
  • [6] Transgender Women's Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)
    Rael, Christine Tagliaferri
    Lopez-Rios, Javier
    McKenna, Stacey A.
    Das, Doyel
    Dolezal, Curtis
    Abascal, Elena
    Carballo-Dieguez, Alex
    Schnall, Rebecca
    Hope, Thomas J.
    Bauermeister, Jose
    Bockting, Walter
    AIDS AND BEHAVIOR, 2021, 25 (12) : 4180 - 4192
  • [7] Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results
    Ruane, P. J.
    Clarke, A.
    Post, F. A.
    Schembri, G.
    Jessen, H.
    Trottier, B.
    Bergin, C.
    Molina, J-M
    Wong, P.
    Ebrahimi, R.
    Brainard, D. M.
    Osinusi, A.
    Das, M.
    McCallister, S.
    HIV MEDICINE, 2019, 20 : 95 - 96
  • [8] DISCOVER in Europe: a sub-analysis of the phase 3 randomized, controlled trial of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP)
    Post, F.
    Spinner, C.
    Coll, P.
    Hawkins, T.
    Anderson, J.
    Zhong, L.
    McCallister, S.
    HIV MEDICINE, 2019, 20 : 243 - 244
  • [9] HPTN 083 interim results: Efficacy of pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is maintained across regions and key populations
    Grinsztejn, B.
    Donnell, D.
    Clement, M.
    Hanscom, B.
    Cottle, L.
    Coelho, L.
    Cabello, R.
    Chariyalestak, S.
    Dunne, E.
    Frank, I.
    Gaur, A.
    Gonzalez, P.
    Ha, T. V.
    Hinojosa, J.
    Kallas, E.
    Kelley, C.
    Losso, M.
    Madruga, J. Valdez
    Middelkoop, K.
    Phanuphak, N.
    Gallardo, J.
    Santos, B.
    Sued, O.
    Huanami, J. Valencia
    Hucks-Ortiz, C.
    Cardozo, N.
    Monteiro, L.
    Promjantuek, K.
    Mvula, X.
    Jones, D.
    Eshleman, S.
    Blanchette, C.
    Lucas, J.
    Scott, H.
    Fields, S.
    Gomez-Feliciano, K.
    Jennings, A.
    Rooney, J.
    Spreen, W.
    Margolis, D.
    Rinehart, A.
    Adeyeye, A.
    Cohen, M.
    McCauley, M.
    Landovitz, R.
    Vela, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 174 - 175
  • [10] Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in the multicenter global HIV Prevention Trials Network 083 (HPTN 083) Study
    Landovitz, R.
    Gao, F.
    Fogel, J. M.
    Hanscom, B.
    Clement, M.
    Tran, H. V.
    Gaur, A. H.
    Fichtenbaum, C. J.
    Piwowar-Manning, E.
    Moser, A.
    Marzinke, M. A.
    Mellors, J.
    Halvas, E. K.
    McCauley, M.
    Gomez-Feliciano, K.
    Jennings, A.
    Soto-Torres, L.
    Zwerski, S.
    Rooney, J. F.
    Acuipil, C.
    Rinehart, A. R.
    Cohen, M. S.
    Grinsztejn, B.
    Eshleman, S. H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 97 - 97
12